Lite Strategy LITS
NASDAQ LITS
$1.06 +0.00 (+0.00%)
At close: Sep 10, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Share-based Compensation (2010 - 2026)

Lite Strategy (LITS) posted Share-based Compensation of $270000.0 for Q1 2026, up 101.72% on a QoQ basis from -$15.7 million in Q4 2025, and down 85.41% year-over-year from $1.9 million in Q1 2025.

Analysis

Lite Strategy (LITS) Share-based Compensation (2010 - 2026) Analysis & Trends

Lite Strategy has reported Share-based Compensation for 17 years, with the latest figure at $270000.0 in Q1 2026.

  • On a quarterly basis, Share-based Compensation fell 85.41% year-over-year to $270000.0 in Q1 2026; TTM through Mar 2026 was $866000.0, a 53.21% decrease from a year earlier, with the FY2025 full-year figure at $869148.0, down 61.85% from the prior year.
  • Share-based Compensation was $270000.0 for Q1 2026 at Lite Strategy, up from -$15.7 million in the prior quarter.
  • The five-year high for Share-based Compensation was $1.4 billion in Q4 2023, with the low at -$15.7 million in Q4 2025.
  • Average Share-based Compensation over 5 years is $177.3 million, with a median of $1.4 million recorded in 2023.
  • The sharpest annual moves came in 2024 and 2025: Share-based Compensation jumped 109520.32% in 2024, then tumbled 1744.14% in 2025.
  • Over 5 years, Share-based Compensation stood at $25.4 million in 2022, then surged by 5401.89% to $1.4 billion in 2023, then plunged by 99.93% to $954723.0 in 2024, then sank by 1744.14% to -$15.7 million in 2025, then jumped by 101.72% to $270000.0 in 2026.
  • The last three Share-based Compensation figures came in at $270000.0 (Q1 2026), -$15.7 million (Q4 2025), and $16.2 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 247.00 Mn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 231.00 Mn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 108.10 Mn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 243.00 Mn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 120.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 86.63 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 77.40 Mn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 83.34 Mn
10 Lite Strategy 38.03 Mn 30.49 Mn - 270,000.00
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 270,000.00
Dec 31, 2025 -15.70 Mn
Sep 30, 2025 16.22 Mn
Jun 30, 2025 78,000.00
Mar 31, 2025 1.85 Mn
Dec 31, 2024 954,723.00
Sep 30, 2024 1.12 Mn
Jun 30, 2024 397,000.00
Mar 31, 2024 1.37 Bn
Dec 31, 2023 1.40 Bn
Sep 30, 2023 1.45 Mn
Mar 31, 2023 1.25 Mn
Dec 31, 2022 25.40 Mn
Sep 30, 2022 11.83 Mn
Jun 30, 2022 650,000.00
Mar 31, 2022 20.59 Mn
Dec 31, 2021 27.38 Mn
Sep 30, 2021 20.64 Mn
Jun 30, 2021 1.56 Mn
Mar 31, 2021 2.65 Mn